PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase iii study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 2, 2014, Pages 205-213

  Reck, Martin ^a   Paz Ares, Luis G ^b   De Marinis, Filippo ^c   Molinier, Olivier ^d   Sahoo, Tarini Prasad ^e   Laack, Eckart ^f   John, William ^g   Zimmermann, Annamaria H ^g   Visseren Grul, Carla ^g   Gridelli, Cesare ^h  

^a Lungen Clinic Groshansdorf   (Germany)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d Le Mans Regional Hospital   (France)

^e Jawaharlal Nehru Cancer Hospital & Research Centre Bhopal   (India)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g ELI LILLY AND COMPANY   (United States)

^h S G MOSCATI HOSPITAL   (Italy)

Author keywords

Cisplatin; Induction; Maintenance; Nonsquamous non small cell lung cancer; Pemetrexed; Phase III; Survival

Indexed keywords

CISPLATIN; PEMETREXED; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KAPLAN MEIER METHOD; KIDNEY FAILURE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84893369941     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000076     Document Type: Article

References (26)

1. NCCN National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-Small Cell Lung Cancer Version 3.2012. Available at: http://www.nccn.org/professionals/ physician-gls/-rfvt- guidelines.asp#nscl. Accessed April 16, 2013.
2. Azzoli CG, Temin S, Aliff T, et al; American Society of Clinical Oncology. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV nonsmall- cell lung cancer. J Clin Oncol 2011;29:3825-3831.
3. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(7 Suppl):vii56-vii64.
4. Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 2013;31:1009-1020.
5. Cappuzzo F, Ciuleanu T, Stelmakh L, et al; SATURN Investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
6. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113-4120.
7. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
8. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2010;13:247-255.
9. Paz-Ares L, De Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. J Clin Oncol 2013;31:2895-2902.
10. Coudert B, Ciuleanu T, Park K, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012;23:388-394.
11. Prol M, Chouaid C, Prol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516-3524.
12. Paz-Ares LG, Altug S, Vaury AT, et al. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer 2010;10:85.
13. Fleming ID, Cooper JS, Henson DE. Lung. In ID Fleming, JS Cooper, DE Henson, et al (Eds.), AJCC Cancer Staging Manual, 5th Ed. Philadelphia, PA: Lippincott-Raven, 1997. Pp. 127-137.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 8/2006 update. Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm#ctc-30. Accessed June 12, 2013.
17. Cox DR, Snell EJ. Analysis of Binary Data, 2nd Ed. London, England: Chapman & Hall, 1989.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Gridelli C, de Marinis F, Pujol JL, et al. Safety, resource use, and quality of life in PARAMOUNT: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2012;7:1713-1721.
20. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
21. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV nonsmall cell lung cancer. Chest 2003;123(1 Suppl):226S-243S.
22. Obasaju C, Bowman L, Wang P, et al. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). Ann Oncol 2013;24:1534-1542.
23. Sun JM, Park JO, Won YW, et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol 2010;5:540-545.
24. Brodowicz T, Krzakowski M, Zwitter M, et al; Central European Cooperative Oncology Group (CECOG). Cisplatin and gemcitabine firstline chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163.
25. Belani C. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced nonsmall cell lung cancer (NSCLC). Oral presentation presented at the American Society of Clinical Oncology (ASCO) Conference, Chicago, IL, June 4-8, 2010; abstract 7506: slide 17.
26. Edelman MJ, Le Chevalier T, Soria J-C. Maintenance therapy and advanced non-small-cell lung cancer: a skeptics view. J Thorac Oncol 2012;7:1331-1336.